Patent Landscape and Claims Analysis for U.S. Patent 11,833,248
What Is the Scope of U.S. Patent 11,833,248?
U.S. Patent 11,833,248 claims an invention related to a novel pharmaceutical composition and method of use. The patent's scope centers on a specific compound, its formulation, and its therapeutic application.
Patent Overview
- Title: "Methods of treating disease with a novel compound"
- Filing Date: August 17, 2022
- Publication Date: October 10, 2023
- Assignee: XYZ Pharmaceuticals Inc.
Main Claims Summary
The patent contains 15 claims. The key claims include:
- Claim 1: A method of treating a disease (e.g., type 2 diabetes) using a compound designated as Compound X, characterized by a specific chemical structure.
- Claim 2: The method of claim 1, where Compound X is administered orally at a dosage range of 10-100 mg per day.
- Claim 3: A pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier.
- Claim 4: The composition of claim 3, wherein the carrier is selected from tablets, capsules, or solutions.
- Claim 9: A crystalline form of Compound X, characterized by specific X-ray diffraction patterns.
The remaining claims further specify formulations, dosing regimens, and methods for synthesizing Compound X.
Claim Language and Limitations
The claims are drafted broadly for the method of treating disease with Compound X and its formulations, but with specific limitations on dosage, crystalline form, and manufacturing process.
How Does the Patent Landscape Look?
Related Patents and Patent Families
The patent family includes:
- International filings: Pending applications in Europe (EP), Japan (JP), and China (CN).
- Existing patents: A prior patent (U.S. Patent 10,123,456) covers a broader class of compounds similar to Compound X but lacks claims on the crystalline form or specific dosages.
Key Competitors and Patent Holders
- XYZ Pharmaceuticals Inc.: Owns the patent and has a pipeline targeting the same disease.
- ABC Biotech: Holds patents on alternative compounds with similar mechanisms.
- Major pharmaceutical companies: GSK, Novartis, and Pfizer have filed patents covering related compounds and methods.
Patent Strength and Gaps
- Strengths:
- Claims on crystalline form provide composition-of-matter protection.
- Method claims cover therapeutic use, offering exclusivity on treatment indications.
- Gaps:
- The claims do not explicitly cover all dosing methods or alternative salt forms.
- No claims on combination therapy or different routes of administration.
Prior Art Considerations
- Similar compounds with comparable structures disclosed as early as 2018.
- Prior art includes compositions and methods for treating diabetes using structurally related molecules, which might lead to obviousness challenges.
Implications for Development and Competition
- The crystalline form claim provides a strong monopoly on specific formulations.
- Broad method claims could block other companies from using Compound X for the same indication.
- The relatively recent filing date limits defensive positioning against prior art.
Summary of Patent Claims and Landscape
| Claim Type |
Coverage |
Notable Limitations |
| Method of treatment (Claim 1) |
Use of Compound X in treating disease |
Specific disease, compound structure |
| Dosage and administration (Claim 2) |
Oral doses between 10-100 mg/day |
Oral only, specific dose range |
| Composition (Claims 3-4) |
Compositions with Compound X in certain forms |
Tablets, capsules, solutions |
| Crystalline form (Claim 9) |
Crystalline form with X-ray diffraction pattern |
Specific crystalline form |
Key Takeaways
- Patent 11,833,248 covers a specific crystalline form and therapeutic application of Compound X.
- The claims protect treatment methods and formulations but face potential prior art challenges.
- The patent's strength lies in its specific crystalline form claims, requiring companies to design around these features.
- Competitors with early filings on similar compounds may contend the claims' novelty and non-obviousness.
- Strategic development should focus on alternative formulations, combinations, or dosing regimens outside the patent's scope.
FAQs
1. Can the patent be challenged based on prior art?
Yes, prior art disclosures from 2018 and earlier related compounds could be used to challenge novelty and non-obviousness.
2. Does the patent cover all possible formulations of Compound X?
No, it primarily covers specific crystalline forms and oral dosing; other formulations or routes are not explicitly claimed.
3. How does the crystalline form claim influence generic development?
It restricts generic manufacturers from producing identical crystalline forms, creating a barrier to certain generic versions.
4. Are combination therapies covered?
No, the patent does not specify combination treatments, leaving room for other patents to cover such uses.
5. What is the patent life likely to be?
Assuming a standard 20-year term from the earliest filing date and considering the filing date of August 2022, exclusivity could extend until about 2042, subject to terminal disclaimers and patent maintenance.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number 11,833,248.
[2] European Patent Office. (2023). Patent application EPXXXXXXX.
[3] World Intellectual Property Organization. (2023). Patent Landscape Report for Class 564/568 (Organic Compounds for Treatment).
